Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Scynexis Inc
NASDAQ SCYX
Data sourced from
and
and
Download Data
Scynexis Inc Price to Book Ratio (P/B) on June 03, 2024: 1.21
Scynexis Inc Price to Book Ratio (P/B) is 1.21 on June 03, 2024, a 131.93% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
-
Scynexis Inc 52-week high Price to Book Ratio (P/B) is 1.87 on September 01, 2023, which is 54.39% above the current Price to Book Ratio (P/B).
-
Scynexis Inc 52-week low Price to Book Ratio (P/B) is -4.82 on June 29, 2023, which is -497.36% below the current Price to Book Ratio (P/B).
-
Scynexis Inc average Price to Book Ratio (P/B) for the last 52 weeks is 0.68.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: SCYX
| CEO | Dr. Marco Taglietti M.D. |
| IPO Date | May 2, 2014 |
| Location | United States |
| Headquarters | 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Key trends
Similar companies
Eagle Pharmaceuticals Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email